Anti-RANKL antibody [C1] (ab239607)
Key features and details
- Mouse monoclonal [C1] to RANKL
- Suitable for: WB, IHC-P
- Reacts with: Rat
- Isotype: IgG2a
Overview
-
Product name
Anti-RANKL antibody [C1]
See all RANKL primary antibodies -
Description
Mouse monoclonal [C1] to RANKL -
Host species
Mouse -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Rat
Predicted to work with: Mouse -
Immunogen
Recombinant fragment corresponding to Rat RANKL aa 100-250. N-terminal His tag. Expressed in E. coli.
Database link: Q9ESE2 -
Positive control
- IHC-P: Rat spinal cord tissue. WB: Recombinant rat RANKL protein. Rat thymus tissue lysate.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 44.12% PBS, 55.77% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Protein A/G purified -
Purification notes
Purified from TCS. -
Clonality
Monoclonal -
Clone number
C1 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab239607 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use a concentration of 0.5 - 5 µg/ml. Predicted molecular weight: 35 kDa.
|
|
IHC-P |
Use a concentration of 5 - 30 µg/ml.
|
Notes |
---|
WB
Use a concentration of 0.5 - 5 µg/ml. Predicted molecular weight: 35 kDa. |
IHC-P
Use a concentration of 5 - 30 µg/ml. |
Target
-
Function
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. -
Tissue specificity
Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. -
Involvement in disease
Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. -
Sequence similarities
Belongs to the tumor necrosis factor family. -
Post-translational
modificationsThe soluble form of isoform 1 derives from the membrane form by proteolytic processing (By similarity). The cleavage may be catalyzed by ADAM17. -
Cellular localization
Cytoplasm; Secreted and Cell membrane. - Information by UniProt
-
Database links
- Entrez Gene: 21943 Mouse
- Entrez Gene: 117516 Rat
- SwissProt: O35235 Mouse
- SwissProt: Q9ESE2 Rat
- Unigene: 249221 Mouse
- Unigene: 217570 Rat
- Unigene: 64517 Rat
-
Alternative names
- CD254 antibody
- hRANKL2 antibody
- ODF antibody
see all
Images
-
Formalin-fixed, paraffin-embedded rat spinal cord tissue stained for RANKL with ab239607 at 20 µg/ml in immunohistochemical analysis. DAB staining.
-
Anti-RANKL antibody [C1] (ab239607) at 5 µg/ml + Rat thymus tissue lysate
Secondary
HRP-Goat Anti-Mouse IgG
Predicted band size: 35 kDa -
Anti-RANKL antibody [C1] (ab239607) at 5 µg/ml + Recombinant rat RANKL protein
Predicted band size: 35 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (7)
ab239607 has been referenced in 7 publications.
- Wu X et al. Melatonin Attenuates Intervertebral Disk Degeneration via Maintaining Cartilaginous Endplate Integrity in Rats. Front Physiol 12:672572 (2021). PubMed: 34220535
- Zhou Y et al. Globular adiponectin inhibits osteoblastic differentiation of vascular smooth muscle cells through the PI3K/AKT and Wnt/β-catenin pathway. J Mol Histol 52:1067-1080 (2021). PubMed: 34398360
- Yu X et al. lncRNA SNHG1 induced by SP1 regulates bone remodeling and angiogenesis via sponging miR-181c-5p and modulating SFRP1/Wnt signaling pathway. Mol Med 27:141 (2021). PubMed: 34732133
- Jiang Y et al. Mechanosensitive Piezo1 in Periodontal Ligament Cells Promotes Alveolar Bone Remodeling During Orthodontic Tooth Movement. Front Physiol 12:767136 (2021). PubMed: 34880779
- Tomaszewska E et al. The Influence of Prenatal Fumonisin Exposure on Bone Properties, as well as OPG and RANKL Expression and Immunolocalization, in Newborn Offspring Is Sex and Dose Dependent. Int J Mol Sci 22:N/A (2021). PubMed: 34948030
- Deng C et al. Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis. Nat Commun 12:2174 (2021). PubMed: 33846342
- Zhou L et al. Doxorubicin restrains osteogenesis and promotes osteoclastogenesis in vitro. Am J Transl Res 12:5640-5654 (2020). PubMed: 33042445